文献速递妇科

血管加压素控制子宫切除术中出血的系统综述与Meta分析

Vasopressin to Control Blood Loss during Hysterectomy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · J Minim Invasive Gynecol · 2021-10-12

该研究系统检索5个数据库,纳入7项随机对照试验共455例患者,比较血管加压素与生理盐水在子宫切除术中控制出血的效果。

要点

  • 血管加压素显著减少子宫切除术中估计失血量,平均减少119.85 mL。
  • 血管加压素不增加发热、盆腔感染、输血及围术期并发症风险。
  • 多数纳入研究为阴式子宫切除术,缺乏腹腔镜子宫切除术数据。

核心结论

  • 与生理盐水相比,血管加压素显著减少子宫切除术中估计失血量,但未改变临床显著结局。
  • 血管加压素安全,未增加发热或盆腔感染率。

研究设计与样本

  • 系统综述与Meta分析,纳入7项随机对照试验,共455例患者(血管加压素组232例,对照组223例)。
  • 检索PubMed、Scopus、Web of Science、Embase和Cochrane Central Register of Controlled Trials,从建库至2021年7月18日,无语言限制。
  • 纳入标准:接受子宫切除术的任何指征患者,干预为血管加压素,对照为生理盐水、安慰剂或无治疗,设计为随机对照试验。
  • 使用Review Manager 5.4.0进行统计分析,合并效应量为均数差(MD)或风险比(RR)及95%置信区间(CI)。
  • 纳入研究中5项为阴式子宫切除术,2项为腹式子宫切除术,无腹腔镜子宫切除术。

主要发现

  • 两组在平均手术时间、术后血红蛋白平均变化、平均住院时间、发热率、盆腔感染率、围术期输血率及围术期并发症率方面无显著差异。

临床怎么用

  • 在子宫切除术中可考虑使用血管加压素以减少术中出血,但需注意现有证据主要来自阴式子宫切除术。
  • 血管加压素未显示增加发热、盆腔感染或输血风险,安全性可接受。

局限性

  • 纳入研究以阴式子宫切除术为主,缺乏腹腔镜子宫切除术的数据。
  • 样本量较小(共455例),可能影响次要结局的统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Minimizing intraoperative blood loss during hysterectomy is crucial to lessen associated perioperative morbidity. The aim of this investigation is to conduct a systematic review and meta-analysis of all randomized controlled trials (RCTs) that compared vasopressin versus normal saline in controlling intraoperative blood loss during hysterectomy. DATA SOURCES: We screened 5 major databases (PubMed, Scopus, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials) from inception till July 18, 2021. We used the following query search in all databases: (vasopressin OR arginine vasopressin OR argipressin OR antidiuretic hormone) AND (hysterectomy) AND (saline OR placebo OR control OR no treatment) AND (randomized OR randomised OR randomly). There was no language restriction during database screening. METHODS OF STUDY SELECTION: We considered all studies that met the following evidence-based criteria: (1) patients: individuals undergoing hysterectomy for any indication, (2) intervention: vasopressin, (3) comparator: normal saline, placebo, or no treatment, (4) outcomes: reliable extraction of any of our endpoints, and (5) study design: RCTs. We assessed risk of bias of included studies and pooled endpoints as mean difference (MD) or risk ratio (RR) with 95% confidence interval (CI). We performed statistical analysis using the Review Manager software, version 5.4.0. TABULATION, INTEGRATION, AND RESULTS: Seven RCTs with an overall low risk of bias met the inclusion criteria. This meta-analysis included a total of 455 patients; 232 and 223 patients were allocated to vasopressin and control group, respectively. The majority of RCTs were vaginal hysterectomy (n = 5), few abdominal hysterectomy, (n = 2) and no laparoscopic hysterectomy. The mean estimated intraoperative blood loss was significantly lower in favor of the vasopressin group compared with the control group (n = 6 RCTs, MD = -119.85 mL, 95% CI [-177.55, -62.14], p <.001). However, there was no significant difference between both groups regarding mean operating time, mean change in postoperative hemoglobin, mean hospital stay, rate of febrile morbidity, rate of pelvic infection, rate of perioperative blood transfusion, and rate of perioperative complications. CONCLUSION: Compared with normal saline, vasopressin significantly reduced the estimated blood loss during hysterectomy but did not change any clinically significant outcomes. In addition, vasopressin was safe and did not correlate with an increase in the rates of febrile morbidity or pelvic infection.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Hafidh B, Latifah HM, Gari A, et al. Vasopressin to Control Blood Loss during Hysterectomy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Minim Invasive Gynecol. 2021. PMID: 34648933. doi:10.1016/j.jmig.2021.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。